{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9"},{"groupId":"OG001","value":"41.4"}]}],"title":"Clinical response (CR, BM-CR, PR, HI)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"},{"groupId":"OG001","value":"6.9"}]}],"title":"Complete remission (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9"},{"groupId":"OG001","value":"3.4"}]}],"title":"Bone marrow CR (BM-CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"6.9"}]}],"title":"Partial remission (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"Best overall response as measured by complete remission (CR) or bone marrow CR (BM-CR) or partial remission (PR) or hematologic improvement (HI).\n\nOverall response patients achieved other than the composite CR by individual response category: CR, CRi, mCR or PR as defined by the International Working Group (IWG) response criteria.","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS): Consisted of all patients who were randomized to one of the two treatment arms.","reportingStatus":"POSTED","timeFrame":"48 months","title":"Overall Response Rate (ORR) Assessed by Best Overall Response: Participants With MDS/CMML Per Investigator (Phase Llb)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}